{
    "title": "113_hr5805",
    "content": "The Act may be cited as the Andrea Sloan Compassionate Use Reform and Enhancement Act or the Andrea Sloan CURE Act. Expanded access policy is required for expedited approval. Section 561 of the Federal Food, Drug, and Cosmetic Act is amended to require an Expanded Access Policy for Covered Breakthrough Drugs within 30 days of meeting the definition. The sponsor must submit and publicly share their policy regarding requests under subsection (b). The policy for Covered Breakthrough Drugs must include a single point of contact, procedures for making requests, criteria for consideration, and decision-making timeline. A Covered Breakthrough Drug is designated as a breakthrough therapy, fast track product, approved under accelerated approval, or designated as a qualified infectious disease product. The policy for Covered Breakthrough Drugs must include a single point of contact, procedures for making requests, criteria for consideration, and decision-making timeline. A Covered Breakthrough Drug is designated as a breakthrough therapy, fast track product, approved under accelerated approval, or designated as a qualified infectious disease product with a priority review voucher. SEC. 3. NOTIFICATION OF SUBMITTERS OF COMPASSIONATE USE REQUESTS. Manufacturers or distributors must notify requesters of denials within 5 days, providing an explanation for the denial. SEC. 4. GAO QUALITATIVE ANALYSIS ON INDIVIDUAL PATIENT ACCESS TO UNAPPROVED THERAPIES AND DIAGNOSTICS. The Comptroller General of the United States must submit an annual report to specific committees analyzing patient access to investigational drugs and providing recommendations for improvement. The report will include an analysis of patterns in access requests and reasons for denials. The annual report must analyze patient access to investigational drugs, including barriers to granting requests, evaluation of safety and efficacy data, processing times for requests by physicians, drug sponsors, and the Secretary, and potential modifications to reduce delays in approving requests. The annual report must analyze patient access to investigational drugs, including barriers to granting requests, evaluation of safety and efficacy data, processing times for requests by physicians, drug sponsors, and the Secretary, and potential modifications to reduce delays in approving requests. The report should also include information on the number of approved, denied, and pending requests for expanded access, ways to encourage drug sponsors to grant requests, and the impact of adverse events on the development or approval of investigational drugs or devices. SEC. 5. EXPANDED ACCESS TASK FORCE. The Secretary of Health and Human Services will establish the Expanded Access Task Force to improve access to investigational drugs for individual patients. The Task Force will have up to 9 voting members, with the Chairman appointed by the Speaker of the House of Representatives. The Expanded Access Task Force will include representatives appointed by the Speaker of the House, the Department of Health and Human Services, and the Majority Leader of the House of Representatives. These representatives will come from various backgrounds, including biopharmaceutical companies and the rare disease patient community. The Expanded Access Task Force will consist of representatives appointed by different entities, including the Speaker of the House, the Department of Health and Human Services, the Majority Leader of the House of Representatives, and the Majority Leader of the Senate. The Task Force members will come from diverse backgrounds such as biopharmaceutical companies, the patient community, health care providers, bioethicists, and health care payors. Members will serve without compensation. The Task Force members will evaluate access to investigational drugs for patients with fatal diseases, consider incentives for companies to approve requests, interpret adverse event data, and streamline the approval process. The Task Force will submit a report with recommendations for improving access to investigational drugs for individual patients with serious diseases. The Task Force will terminate upon submitting the report required under subsection (d) of the Federal Food, Drug, and Cosmetic Act. SEC. 6. FINALIZING DRAFT GUIDANCE ON EXPANDED ACCESS. The Secretary of Health and Human Services must finalize the draft guidance on Expanded Access to Investigational Drugs within 180 days of receiving the report from the Expanded Access Task Force. The guidance will define how adverse drug event data is interpreted and consider reports from the Task Force and the Comptroller General."
}